Gema Requena1, Achim Wolf2, Rachael Williams2, Daniel Dedman2, Jennifer K Quint3, Tarita Murray-Thomas2, Jeanne M Pimenta1. 1. Respiratory Epidemiology, GlaxoSmithKline, Brentford, UK. 2. Clinical Practice Research Datalink, Medicines and Healthcare Products Regulatory Agency, London, UK. 3. Respiratory Epidemiology, Occupational Medicine and Public Health, National Heart and Lung Institute, Imperial College London, London, UK.
Abstract
PURPOSE: To assess the feasibility of using Clinical Practice Research Datalink (CPRD) data for identifying populations of patients with chronic obstructive pulmonary disease (COPD) eligible for a hypothetical pragmatic trial. METHODS: A retrospective multidatabase cohort study using CPRD primary care and linked secondary care data to describe the characteristics of populations of patients with COPD. Patients' demographic and lifestyle factors, comorbidity profile, spirometry measurements and treatment changes were evaluated, as was the distribution of follow-up time and types of losses during follow-up. Characteristics were evaluated using descriptive statistics. RESULTS: A total of 322 991 patients from 1148 primary care practices in the United Kingdom across two CPRD primary care databases, CPRD GOLD and CPRD Aurum, were potentially eligible to participate in a hypothetical trial using CPRD, starting on 31 December 2017. Patients with COPD in CPRD GOLD and CPRD Aurum were comparable in terms of age (median age 70 vs. 68 years), gender (50% vs. 52% male), disease severity (e.g., 25% vs. 24% Medical Research Council [MRC] dyspnoea score grades 3-5) and history of respiratory conditions (e.g., 43% vs. 38% asthma). High proportions of patients with COPD in CPRD GOLD and CPRD Aurum were available on 31 December 2012 for follow-up at 1, 2, and 5 years (92%, 85% and 67%, respectively). CONCLUSIONS: Patients and data from CPRD GOLD and CPRD Aurum were comparable across key aspects relevant to COPD trials. A pragmatic trial using CPRD to recruit patients with COPD is scientifically feasible.
PURPOSE: To assess the feasibility of using Clinical Practice Research Datalink (CPRD) data for identifying populations of patients with chronic obstructive pulmonary disease (COPD) eligible for a hypothetical pragmatic trial. METHODS: A retrospective multidatabase cohort study using CPRD primary care and linked secondary care data to describe the characteristics of populations of patients with COPD. Patients' demographic and lifestyle factors, comorbidity profile, spirometry measurements and treatment changes were evaluated, as was the distribution of follow-up time and types of losses during follow-up. Characteristics were evaluated using descriptive statistics. RESULTS: A total of 322 991 patients from 1148 primary care practices in the United Kingdom across two CPRD primary care databases, CPRD GOLD and CPRD Aurum, were potentially eligible to participate in a hypothetical trial using CPRD, starting on 31 December 2017. Patients with COPD in CPRD GOLD and CPRD Aurum were comparable in terms of age (median age 70 vs. 68 years), gender (50% vs. 52% male), disease severity (e.g., 25% vs. 24% Medical Research Council [MRC] dyspnoea score grades 3-5) and history of respiratory conditions (e.g., 43% vs. 38% asthma). High proportions of patients with COPD in CPRD GOLD and CPRD Aurum were available on 31 December 2012 for follow-up at 1, 2, and 5 years (92%, 85% and 67%, respectively). CONCLUSIONS:Patients and data from CPRD GOLD and CPRD Aurum were comparable across key aspects relevant to COPD trials. A pragmatic trial using CPRD to recruit patients with COPD is scientifically feasible.
Keywords:
chronic obstructive pulmonary disease; electronic health record; feasibility studies; general practice; primary health care; real world clinical trials
Authors: Louis P Garrison; Peter J Neumann; Pennifer Erickson; Deborah Marshall; C Daniel Mullins Journal: Value Health Date: 2007 Sep-Oct Impact factor: 5.725
Authors: Evangelos Kontopantelis; Richard John Stevens; Peter J Helms; Duncan Edwards; Tim Doran; Darren M Ashcroft Journal: BMJ Open Date: 2018-02-28 Impact factor: 2.692
Authors: Jennifer K Quint; Elisabeth Moore; Adam Lewis; Maimoona Hashmi; Kirin Sultana; Mark Wright; Liam Smeeth; Lia Chatzidiakou; Roderic Jones; Sean Beevers; Sefki Kolozali; Frank Kelly; Benjamin Barratt Journal: NPJ Prim Care Respir Med Date: 2018-06-19 Impact factor: 2.871
Authors: Daniel Dedman; Sonia J Coton; Rebecca E Ghosh; Wilhelmine Meeraus; Courtney Crim; Catherine Harvey; Justyna Amelio; Sarah H Landis Journal: Pulm Ther Date: 2019-04-24
Authors: Gema Requena; Achim Wolf; Rachael Williams; Daniel Dedman; Jennifer K Quint; Tarita Murray-Thomas; Jeanne M Pimenta Journal: Pharmacoepidemiol Drug Saf Date: 2021-01-09 Impact factor: 2.890
Authors: Tjeerd-Pieter van Staa; Lisa Dyson; Gerard McCann; Shivani Padmanabhan; Rabah Belatri; Ben Goldacre; Jackie Cassell; Munir Pirmohamed; David Torgerson; Sarah Ronaldson; Joy Adamson; Adel Taweel; Brendan Delaney; Samhar Mahmood; Simona Baracaia; Thomas Round; Robin Fox; Tommy Hunter; Martin Gulliford; Liam Smeeth Journal: Health Technol Assess Date: 2014-07 Impact factor: 4.014
Authors: Jennifer K Quint; Hana Müllerova; Rachael L DiSantostefano; Harriet Forbes; Susan Eaton; John R Hurst; Kourtney Davis; Liam Smeeth Journal: BMJ Open Date: 2014-07-23 Impact factor: 2.692
Authors: Gema Requena; Achim Wolf; Rachael Williams; Daniel Dedman; Jennifer K Quint; Tarita Murray-Thomas; Jeanne M Pimenta Journal: Pharmacoepidemiol Drug Saf Date: 2021-01-09 Impact factor: 2.890
Authors: Dahai Yu; Matthew Missen; Kelvin P Jordan; John J Edwards; James Bailey; Ross Wilkie; Justine Fitzpatrick; Nuzhat Ali; Paul Niblett; George Peat Journal: Clin Epidemiol Date: 2022-02-17 Impact factor: 4.790